Suppliers and packagers for VIAGRA

VIAGRA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895	NDA	PFIZER LABORATORIES DIV PFIZER INC	0069-4200-30	30 TABLET, FILM COATED in 1 BOTTLE (0069-4200-30)	1998-03-27
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895	NDA	PFIZER LABORATORIES DIV PFIZER INC	0069-4210-30	30 TABLET, FILM COATED in 1 BOTTLE (0069-4210-30)	1998-03-27
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895	NDA	PFIZER LABORATORIES DIV PFIZER INC	0069-4210-66	100 TABLET, FILM COATED in 1 BOTTLE (0069-4210-66)	1998-03-27
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895	NDA	PFIZER LABORATORIES DIV PFIZER INC	0069-4220-30	30 TABLET, FILM COATED in 1 BOTTLE (0069-4220-30)	1998-03-27

Viagra Suppliers (Sildenafil) 2026: Contract Manufacturers, API Sources, and Supply Chain Risks

Last updated: May 28, 2026

Executive summary: Pfizer manufactures and supplies Viagra (sildenafil) through internal and contracted manufacturing channels, with active pharmaceutical ingredient (API) and finished-dose production performed by multinational pharmaceutical supply networks. Public, regulator-facing data typically identify market authorization holder(s) and manufacturing sites for finished dosage forms rather than a single, fixed “API supplier.” For diligence, the actionable approach is to map (1) FDA drug-application manufacturing sites, (2) API manufacturing and control references used in Pfizer’s submissions, and (3) third-party logistics and secondary packaging sites. This yields a defensible list of suppliers for procurement, operational risk, and IP-enforcement planning.

Who supplies Viagra (sildenafil) finished tablets to the U.S. market?

Answer: Viagra tablets sold in the U.S. are produced at manufacturing sites listed in Pfizer’s FDA submissions and labeled on product packaging. Those sites change over time due to site transfers and packaging model updates, so the supplier list must be tied to the current FDA labeling/manufacturing information for the specific strength (e.g., 25 mg, 50 mg, 100 mg) and to the latest approved manufacturing configuration for that NDC.

What entities typically appear as “manufactured for” on Viagra packaging?

For branded products like Viagra, the label commonly reflects one or more of the following:

• Finished dosage manufacturing site (site that manufactures and tests tablets).
• Packager/secondary packaging site (blistering, bottling, labeling).
• Relabeler or “manufactured for” entity (commercial entity responsible for distribution in region).
• Imprint and strength-specific manufacturing splits, where different strengths can have different fill-finish or packaging sites.

How to operationalize the supplier list for procurement

A procurement-grade supplier map should separate:

• API production (sildenafil free base or citrate salt manufacturing, depending on submission and control strategy).
• Formulation and tablet manufacturing (granulation, compression, coating).
• Packaging (blister versus bottle, labeling, lot serialization depending on market).

Public records that support those tiers are primarily:

• FDA drug product listing and label manufacturing statements (for finished-dose sites).
• Patent and regulatory chemistry references (for API-related manufacturing know-how).
• Corporate procurement and supplier declarations used in audits (for actual vendor qualification).

What companies make the sildenafil API used for Viagra?

Answer: Sildenafil API supply for branded sildenafil products comes from a specialized chemical manufacturing base. In practice, branded manufacturers rely on qualified suppliers and may use multiple API vendors for redundancy and regulatory compliance. However, a single universally stable “API supplier list” for Viagra cannot be determined from high-level public sources alone because Pfizer can qualify additional API sites or switch suppliers while maintaining product equivalence and regulatory approval.

What to look for in regulatory and label artifacts

For a diligence-grade API supplier identification, the supplier evidence typically comes from:

• Drug substance manufacturer(s) named in the application lifecycle (often in CMC documents or supplier change notifications).
• Analytical and release specifications referencing the source and control strategy.
• CoA or audit documentation (not broadly public).

Why branded products complicate the “single API supplier” view

• Multiple API sources can be qualified for continuity of supply.
• Drug substance and drug product sites are frequently in different countries.
• Salt form controls (e.g., citrate conversion) can affect what a supplier is actually providing.

Which contract manufacturing organizations (CMOs) produce Viagra tablets?

Answer: The CMOs producing Viagra tablets are the manufacturing sites named in the current approved product labeling and FDA listings for Viagra’s NDCs. These can include:

• Pfizer manufacturing sites directly.
• Third-party CMOs contracted by Pfizer for tablet manufacture.
• Fill-finish and packaging partners handling blistering/bottling and labeling.

Because manufacturing site configurations change, a correct supplier list must reflect the current labeled manufacturing information for each strength.

What manufacturing steps drive CMO selection

Tablet supply contracts typically split into:

• Milling and blending of excipients and sildenafil
• Wet or dry granulation (process-dependent)
• Compression and coating
• In-process controls and tablet strength verification
• Packaging line qualification and stability study integration

CMO qualification is usually tied to:

• GMP compliance history
• Ability to maintain impurity profiles and polymorph controls
• Analytics capability for sildenafil related substances
• Change control integration with Pfizer’s regulatory strategy

What is the supplier and manufacturing network structure for Viagra (sildenafil) in practice?

Answer: The supply chain for a branded ED therapy typically follows a hub-and-spoke pattern:

1. Drug substance (API) manufactured by one or more chemical suppliers.
2. Drug product tablets manufactured by a tablet CMO or Pfizer site under GMP.
3. Secondary packaging performed at a packaging site (often different from tablet production).
4. Distribution through Pfizer or third-party logistics to regional wholesalers and pharmacy channels.

Supply chain risk points for sildenafil

Key operational risk points include:

• API raw material availability and chemical intermediate sourcing
• Salt form consistency (sildenafil citrate behavior in formulation and stability)
• Polymorph and impurity drift during API switching
• Tablet coating and film integrity during CMO process changes
• Packaging lead times for blisters and labels with local requirements

What FDA status governs Viagra supply and manufacturing under current labeling?

Answer: Viagra is an approved prescription drug with manufacturing details embedded in FDA labeling and the approved application. The “supplier list” that matters for regulatory readiness is the set of approved manufacturing sites associated with the marketed dosage forms.

How to interpret Orange Book and labeling linkages

• The Orange Book is a patent listing and exclusivity reference tool.
• It does not directly enumerate API vendors.
• FDA labeling and the application CMC section provide the manufacturing site details needed for a real supplier roster.

How many suppliers are typically involved for Viagra across API, tablets, and packaging?

Answer: A branded tablet product generally has:

• Multiple API suppliers qualified over the product lifecycle (for continuity and cost optimization).
• One or two primary tablet manufacturing sites for scale.
• One or more packaging sites, sometimes separated by strength or market packaging format.

A procurement-ready plan treats supplier count as a function of redundancy targets, shipping lanes, and qualification timelines rather than a fixed number.

What supplier changes can trigger supply disruptions for Viagra?

Answer: The biggest triggers are:

• API qualification delays after supplier switches
• CMO line shutdowns or capacity bottlenecks
• Packaging material shortages (labels, blister film, cartons)
• Regulatory update processes tied to site changes

For sildenafil, impurity profile control and stability evidence requirements make CMO/API switching non-trivial.

Which generics or biosimilar-like competitors affect Viagra supplier pressure?

Answer: There are no “biosimilars” to Viagra because sildenafil is a small molecule. Competitive pressure mainly comes from generic sildenafil manufacturers. When generics expand capacity, branded supply networks can face:

• raw material price movements,
• API capacity allocation pressure,
• longer lead times for tablet packaging materials.

Key supplier-due-diligence checklist for Viagra procurement

• Confirm approved finished-dose manufacturing sites by NDC and strength from current FDA labeling.
• Separate tablet manufacture from packaging and require documentation for both.
• Request API supplier qualification summaries from Pfizer (or its supply chain delegate) including DMF status where applicable and impurity acceptance criteria.
• Map change-control triggers: how API switching and process parameter changes are handled for sildenafil impurity profiles and stability.
• Validate regional distribution capacity via logistics partners and warehousing lanes, not only manufacturing sites.

Key Takeaways

• Viagra’s “supplier” landscape is best defined by approved finished-dose manufacturing sites named in FDA labeling for each NDC and strength, plus qualified API and packaging partners used in Pfizer’s CMC strategy.
• A single, static API supplier list usually does not exist publicly because branded products commonly use multiple qualified API sources over time.
• Procurement and risk work should map supply chain tiers: API, tablet GMP manufacture, and secondary packaging, then tie each tier to current approval artifacts for the relevant NDCs.
• The most common supply disruption drivers are API qualification timelines, CMO capacity events, and packaging material constraints.

FAQs

1) Is Viagra manufactured by Pfizer or by contract manufacturers?
Viagra tablets are manufactured at GMP sites that can be Pfizer-owned or contract manufacturing sites; the definitive list is the approved manufacturing sites shown in the product’s current labeling for the relevant NDCs.

2) Can Viagra’s API supplier be changed without regulatory action?
API supplier changes typically require CMC change control and may require regulatory updates depending on the change scope and the evidence provided (e.g., comparability and updated controls).

3) Does Orange Book list Viagra manufacturing suppliers?
No. The Orange Book lists patents, exclusivity, and application details. Manufacturing sites are sourced from labeling and regulatory CMC information, not the Orange Book.

4) Are there biosimilars of Viagra that compete in supply?
No. Sildenafil is a small molecule; competition comes from generic sildenafil, not biosimilars.

5) What data best supports supplier qualification for sildenafil tablets?
Approved manufacturing site evidence for the finished dose plus supplier qualification documentation for API and packaging, including impurity control strategy and change-control history.

---

References

1. U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration (FDA). Drug Labeling (access via DailyMed). https://dailymed.nlm.nih.gov/dailymed/